Bone marrow cancer and immuno-oncology research agreement

Australian immuno-oncology company HaemaLogiX has signed an agreement with health and research institutions for commercialisation rights to an immuno-oncology agent designed to specifically target malignant cancer cells present in the bone marrow of multiple myeloma patients.

Westmead Institute for Medical Research, Western Sydney Local Health District, Children’s Medical Research Institute, and the University of Sydney finalised the agreement with HaemaLogiX today. [Read more]